Patients enrolled in the parent study who were seropositive for the hepatitis B surface antigen and had normal liver function , serum HBV DNA levels of less than 103 copies/mL , and no prior antiviral therapy were randomized to entecavir ( n = 61 ) or lamivudine ( n = 60 ) .